EurekaBio is a biotechnology company that offers solutions for cancer immunotherapy including automatic cell therapy manufacturing equipment and a vector production platform. The company was founded in 2014 and is based in Shenzhen, China. EurekaBio closed its last funding round on Jun 21, 2022 from a Series B round.
According to Crunchbase, EurekaBio’s competitors include Ocean Biomedical, Aro Biotherapeutics, and Eureka Therapeutics.
Location: China, Guangdong Province, Shenzhen
Investors 2
| Date | Name | Website |
| 10.03.2024 | F-Prime Ca... | fprimecapi... |
| 23.03.2023 | Eight Road... | eightroads... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 21.02.2024 | Deals in brief: UnoAsia banks USD 32.1 million, Franklin Tem... | UnoAsia banks USD 32.1 million in pre-Series B round UnoAsia, the parent company of Uno Digital Bank... | kr-asia.co... |
| 01.07.2022 | China-based Eurekabio raises Series B financing | Eurekabio, an emerging manufacturing supplies platform for Cell and Gene Therapy (CGT) in China, ann... | eightroads... |
| - | EurekaBio | “EurekaBio is a leading upstream core vendor in the field of Cell and Gene Therapy (CGT), focusing o... | fastfounde... |